Whole genome and transcriptome analysis of metastatic adrenocortical carcinoma

Dr Jean-Michel Lavoie - BC Cancer, Vancouver, Canada
Whole genome and transcriptome analysis of metastatic adrenocortical carcinoma ( Dr Jean-Michel Lavoie - BC Cancer, Vancouver, Canada )
14 Feb 2019

Sacituzumab govitecan in patients with previously treated metastatic urothelial cancer

Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA
Sacituzumab govitecan in patients with previously treated metastatic urothelial cancer ( Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA )
14 Feb 2019

Updates from KEYNOTE 57: Pembrolizumab for patients with bladder cancer

Dr Arjun Balar - NYU Langone Health, New York City, USA
Updates from KEYNOTE 57: Pembrolizumab for patients with bladder cancer ( Dr Arjun Balar - NYU Langone Health, New York City, USA )
14 Feb 2019

CHEIRON study: Docetaxel plus enzalutamide versus docetaxel as first-line chemotherapy for patients with mCRPC

Dr Orazio Caffo - Santa Chiara Hospital, Trento, Italy
CHEIRON study: Docetaxel plus enzalutamide versus docetaxel as first-line chemotherapy for patients with mCRPC ( Dr Orazio Caffo - Santa Chiara Hospital, Trento, Italy )
14 Feb 2019

TRITON2: Evaluation of rucaparib in patients with metastatic castration-resistant prostate cancer

Dr Josep Piulats - IDIBELL, Barcelona, Spain
TRITON2: Evaluation of rucaparib in patients with metastatic castration-resistant prostate cancer ( Dr Josep Piulats - IDIBELL, Barcelona, Spain )
26 Oct 2018

IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in key subgroups with stage IV non-squamous NSCLC

Dr Fabrice Barlesi - Aix-Marseille University, Marseille, France
IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in key subgroups with stage IV non-squamous NSCLC ( Dr Fabrice Barlesi - Aix-Marseille University, Marseille, France )
25 Oct 2018

Pan-cancer assessment of BRCA1/2 genomic alterations by comprehensive genomic profiling of tissue and circulating tumour DNA

Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, Utah
Pan-cancer assessment of BRCA1/2 genomic alterations by comprehensive genomic profiling of tissue and circulating tumour DNA ( Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, Utah )
25 Oct 2018

Assessing radiotherapy for men with newly diagnosed metastatic prostate cancer

Dr Chris C. Parker - The Royal Marsden, London, UK
Assessing radiotherapy for men with newly diagnosed metastatic prostate cancer ( Dr Chris C. Parker - The Royal Marsden, London, UK )
22 Oct 2018

ESMO 2018: Highlights

Prof Gordon McVie , Will Davies
ESMO 2018: Highlights ( Prof Gordon McVie , Will Davies )
22 Oct 2018

Comment on the JAVELIN study: RCC immunotherapy

Prof John Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands
Comment on the JAVELIN study: RCC immunotherapy ( Prof John Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands )
21 Oct 2018

Comment: Radiotherapy as a treatment option for metastatic prostate cancer

Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain
Comment: Radiotherapy as a treatment option for metastatic prostate cancer ( Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain )
21 Oct 2018

JAVELIN Renal 101 trial: avelumab and axitinib for advanced renal cell carcinoma

Dr Robert J. Motzer - Memorial Sloan-Kettering Cancer Center, New York, USA
JAVELIN Renal 101 trial: avelumab and axitinib for advanced renal cell carcinoma ( Dr Robert J. Motzer - Memorial Sloan-Kettering Cancer Center, New York, USA )
21 Oct 2018